{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:46:56Z","timestamp":1783648016591,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T00:00:00Z","timestamp":1496966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s12020-017-1316-3","type":"journal-article","created":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T04:06:35Z","timestamp":1496981195000},"page":"156-165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Long-term treatment of Cushing\u2019s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial"],"prefix":"10.1007","volume":"57","author":[{"given":"S.","family":"Petersenn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. R.","family":"Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schopohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Portocarrero-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Arnaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Scaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. M. K.","family":"Biller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,9]]},"reference":[{"key":"1316_CR1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","volume":"386","author":"A Lacroix","year":"2015","unstructured":"A. Lacroix, R.A. Feelders, C.A. Stratakis, L.K. Nieman, Cushing\u2019s syndrome. Lancet 386, 913\u2013927 (2015)","journal-title":"Lancet"},{"key":"1316_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1210\/er.2013-1048","volume":"36","author":"R Pivonello","year":"2015","unstructured":"R. Pivonello, M. De Leo, A. Cozzolino, A. Colao, The treatment of Cushing\u2019s disease. Endocr. Rev. 36, 385\u2013486 (2015)","journal-title":"Endocr. Rev."},{"key":"1316_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1365-2265.1994.tb02486.x","volume":"40","author":"J Etxabe","year":"1994","unstructured":"J. Etxabe, J.A. Vazquez, Morbidity and mortality in Cushing\u2019s disease: an epidemiological approach. Clin. Endocrinol. 40, 479\u2013484 (1994)","journal-title":"Clin. Endocrinol."},{"key":"1316_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1530\/EJE-11-1095","volume":"167","author":"RA Feelders","year":"2012","unstructured":"R.A. Feelders, S.J. Pulgar, A. Kempel, A.M. Pereira, The burden of Cushing\u2019s disease: clinical and health-related quality of life aspects. Eur. J. Endocrinol. 167, 311\u2013326 (2012)","journal-title":"Eur. J. Endocrinol."},{"key":"1316_CR5","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"L.K. Nieman, B.M. Biller, J.W. Findling et al., Treatment of Cushing\u2019s syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 100, 2807\u20132831 (2015)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1316_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1530\/eje.0.1460707","volume":"146","author":"C Bruns","year":"2002","unstructured":"C. Bruns, I. Lewis, U. Briner, G. Meno-Tetang, G. Weckbecker, SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. 146, 707\u2013716 (2002)","journal-title":"Eur. J. Endocrinol."},{"key":"1316_CR7","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"A. Colao, S. Petersenn, J. Newell-Price et al., A 12-month Phase 3 study of pasireotide in Cushing\u2019s disease. N. Engl. J. Med. 366, 914\u2013924 (2012)","journal-title":"N. Engl. J. Med."},{"key":"1316_CR8","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s11102-014-0618-1","volume":"18","author":"J Schopohl","year":"2015","unstructured":"J. Schopohl, F. Gu, R. Rubens et al., Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing\u2019s disease: results from an open-ended, open-label extension trial. Pituitary 18, 604\u2013612 (2015)","journal-title":"Pituitary"},{"key":"1316_CR9","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cen.12431","volume":"81","author":"R Pivonello","year":"2014","unstructured":"R. Pivonello, S. Petersenn, J. Newell-Price et al., Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing\u2019s disease: results from a Phase III study. Clin. Endocrinol. 81, 408\u2013417 (2014)","journal-title":"Clin. Endocrinol."},{"key":"1316_CR10","first-page":"735489","volume":"2013","author":"C Yedinak","year":"2013","unstructured":"C. Yedinak, J. Brzana, M. Fleseriu, Monitoring patient improvement parameters following pasireotide treatment in Cushing\u2019s disease. Case Rep. Endocrinol. 2013, 735489 (2013)","journal-title":"Case Rep. Endocrinol."},{"key":"1316_CR11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11102-014-0582-9","volume":"18","author":"L Trementino","year":"2015","unstructured":"L. Trementino, M. Cardinaletti, C. Concettoni et al., Up-to 5-year efficacy of pasireotide in a patient with Cushing\u2019s disease and pre-existing diabetes: literature review and clinical practice considerations. Pituitary 18, 359\u2013365 (2015)","journal-title":"Pituitary"},{"key":"1316_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11102-013-0539-4","volume":"17","author":"J Mackenzie Feder","year":"2013","unstructured":"J. Mackenzie Feder, I. Bourdeau, S. Vallette et al., Pasireotide monotherapy in Cushing\u2019s disease: a single-centre experience with 5-year extension of phase III Trial. Pituitary 17, 519\u2013529 (2013)","journal-title":"Pituitary"},{"key":"1316_CR13","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.4158\/EP12296.CR","volume":"19","author":"L Lu","year":"2013","unstructured":"L. Lu, L. Duan, Z. Jin, Z. Lu, F. Gu, Effective long-term treatment of Cushing\u2019s disease with pasireotide\u2014a case report. Endocr. Pract. 19, e92\u2013e96 (2013)","journal-title":"Endocr. Pract."},{"key":"1316_CR14","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s11102-012-0427-3","volume":"15","author":"I Shimon","year":"2012","unstructured":"I. Shimon, L. Rot, E. Inbar, Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review. Pituitary 15, 608\u2013613 (2012)","journal-title":"Pituitary."},{"key":"1316_CR15","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). (2006). http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf"},{"key":"1316_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11102-013-0484-2","volume":"17","author":"X Badia","year":"2014","unstructured":"X. Badia, E. Valassi, M. Roset, S.M. Webb, Disease-specific quality of life evaluation and its determinants in Cushing\u2019s syndrome: what have we learnt? Pituitary 17, 187\u2013195 (2014)","journal-title":"Pituitary"},{"key":"1316_CR17","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s12020-015-0557-2","volume":"50","author":"C Simeoli","year":"2015","unstructured":"C. Simeoli, R.S. Auriemma, F. Tortora et al., The treatment with pasireotide in Cushing\u2019s disease: effects of long-term treatment on tumor mass in the experience of a single center. Endocrine 50, 725\u2013740 (2015)","journal-title":"Endocrine"},{"key":"1316_CR18","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1007\/s12020-015-0754-z","volume":"50","author":"S Petersenn","year":"2015","unstructured":"S. Petersenn, How to manage pasireotide, when using as medical treatment for Cushing\u2019s disease. Endocrine 50, 526\u2013528 (2015)","journal-title":"Endocrine"},{"key":"1316_CR19","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1210\/jc.2013-1771","volume":"98","author":"RR Henry","year":"2013","unstructured":"R.R. Henry, T.P. Ciaraldi, D. Armstrong et al., Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin. Endocrinol. Metab. 98, 3446\u20133453 (2013)","journal-title":"J Clin. Endocrinol. Metab."},{"key":"1316_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s12020-013-0098-5","volume":"46","author":"D Ferone","year":"2014","unstructured":"D. Ferone, C. Pivonello, G. Vitale et al., Molecular basis of pharmacological therapy in Cushing\u2019s disease. Endocrine 46, 181\u2013198 (2014)","journal-title":"Endocrine"},{"key":"1316_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12020-013-0129-2","volume":"47","author":"A Colao","year":"2014","unstructured":"A. Colao, M. Boscaro, D. Ferone, F.F. Casanueva, Managing Cushing\u2019s disease: the state of the art. Endocrine 47, 9\u201320 (2014)","journal-title":"Endocrine"},{"key":"1316_CR22","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2013-3628","volume":"99","author":"F Castinetti","year":"2014","unstructured":"F. Castinetti, L. Guignat, P. Giraud et al., Ketoconazole in Cushing\u2019s disease: is it worth a try? J. Clin. Endocrinol. Metab. 99, 1623\u20131630 (2014)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1316_CR23","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1210\/jc.2015-2616","volume":"100","author":"E Daniel","year":"2015","unstructured":"E. Daniel, S. Aylwin, O. Mustafa et al., Effectiveness of metyrapone in treating Cushing\u2019s syndrome: a retrospective multicenter study in 195 patients. J. Clin. Endocrinol. Metab. 100, 4146\u20134154 (2015)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1316_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12902-015-0059-5","volume":"15","author":"HG Fein","year":"2015","unstructured":"H.G. Fein, T.B. Vaughan III, H. Kushner, D. Cram, D. Nguyen, Sustained weight loss in patients treated with mifepristone for Cushing\u2019s syndrome: a follow-up analysis of the SEISMIC study and long-term extension. BMC Endocr. Disord. 15, 63 (2015)","journal-title":"BMC Endocr. Disord."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-017-1316-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-017-1316-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-017-1316-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T13:44:47Z","timestamp":1567777487000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-017-1316-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,9]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["1316"],"URL":"https:\/\/doi.org\/10.1007\/s12020-017-1316-3","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,9]]},"assertion":[{"value":"9 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"S.P. has served as consultant for Novartis and Ipsen; L.R.S. has served as a consultant for Novartis; J.S. has served as a consultant for Novartis, Ipsen, and Pfizer and has received grants for clinical studies from Novartis, Ipsen, Pfizer, Chiasma, Teva, Sandoz, and Lilly; L.P.O., G.A. and C.S. have no conflicts of interest to report. A.L. has received research support and served as a consultant for Novartis, EMD Serono and Strongbridge Biopharma. S.R. and A.K. are employees of Novartis. B.M.K.B. has served as principal investigator on studies with research grants from Novartis and Cortendo to the Massachusetts General Hospital and as a consultant to Novartis, Cortendo, HRA Pharma, and Ipsen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}